KR102416144B1 - 환자에서 항-cd19 치료법의 치료 이익의 예측 방법 - Google Patents

환자에서 항-cd19 치료법의 치료 이익의 예측 방법 Download PDF

Info

Publication number
KR102416144B1
KR102416144B1 KR1020187038026A KR20187038026A KR102416144B1 KR 102416144 B1 KR102416144 B1 KR 102416144B1 KR 1020187038026 A KR1020187038026 A KR 1020187038026A KR 20187038026 A KR20187038026 A KR 20187038026A KR 102416144 B1 KR102416144 B1 KR 102416144B1
Authority
KR
South Korea
Prior art keywords
lymphoma
cells
sequence
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187038026A
Other languages
English (en)
Korean (ko)
Other versions
KR20190013980A (ko
Inventor
잔 엔델
마크 빈더리치
라이너 박스해머
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20190013980A publication Critical patent/KR20190013980A/ko
Application granted granted Critical
Publication of KR102416144B1 publication Critical patent/KR102416144B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187038026A 2016-05-30 2017-05-30 환자에서 항-cd19 치료법의 치료 이익의 예측 방법 Active KR102416144B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16171885 2016-05-30
EP16171885.3 2016-05-30
PCT/EP2017/063045 WO2017207574A1 (en) 2016-05-30 2017-05-30 Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Publications (2)

Publication Number Publication Date
KR20190013980A KR20190013980A (ko) 2019-02-11
KR102416144B1 true KR102416144B1 (ko) 2022-07-04

Family

ID=56116221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187038026A Active KR102416144B1 (ko) 2016-05-30 2017-05-30 환자에서 항-cd19 치료법의 치료 이익의 예측 방법

Country Status (27)

Country Link
US (2) US20190195879A1 (OSRAM)
EP (2) EP3465214B1 (OSRAM)
JP (2) JP7066639B2 (OSRAM)
KR (1) KR102416144B1 (OSRAM)
CN (2) CN115932265A (OSRAM)
AU (1) AU2017272608B2 (OSRAM)
BR (1) BR112018074603A2 (OSRAM)
CY (1) CY1124768T1 (OSRAM)
DK (2) DK3916392T3 (OSRAM)
EA (1) EA201892542A1 (OSRAM)
ES (2) ES2878156T3 (OSRAM)
FI (1) FI3916392T3 (OSRAM)
HR (2) HRP20210938T1 (OSRAM)
HU (2) HUE054860T2 (OSRAM)
IL (1) IL263103B2 (OSRAM)
LT (2) LT3916392T (OSRAM)
MA (2) MA45124B1 (OSRAM)
MD (2) MD3465214T2 (OSRAM)
MX (2) MX388502B (OSRAM)
PL (2) PL3465214T3 (OSRAM)
PT (2) PT3916392T (OSRAM)
RS (2) RS62155B1 (OSRAM)
SG (2) SG11201810159TA (OSRAM)
SI (2) SI3916392T1 (OSRAM)
SM (2) SMT202400204T1 (OSRAM)
WO (1) WO2017207574A1 (OSRAM)
ZA (2) ZA201808647B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
LT3532098T (lt) 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MA55794A (fr) * 2019-05-03 2022-03-09 Morphosys Ag Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk
KR20220103969A (ko) * 2019-10-31 2022-07-25 모르포시스 아게 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
BR112023010885A2 (pt) * 2020-12-04 2023-10-03 Incyte Corp Terapia de combinação de anti-cd19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195498A1 (en) 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101063278B1 (ko) 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR101335798B1 (ko) * 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
ATE501436T1 (de) 2006-09-13 2011-03-15 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
SG190254A1 (en) 2010-11-15 2013-06-28 Medimmune Llc Combination therapy for b cell lymphomas
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20200058583A (ko) 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
PL2744826T3 (pl) * 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i analogiem puryny
WO2013090478A1 (en) * 2011-12-12 2013-06-20 Pikamab, Inc Predicting responsiveness to antibody maintenance therapy
EP3110445A4 (en) * 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
WO2016005548A1 (en) 2014-07-11 2016-01-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195498A1 (en) 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jennifer A Woyach et al, BLOOD (2014.12.04.), vol 124, no 24, pp 3553-3560

Also Published As

Publication number Publication date
SI3916392T1 (sl) 2024-10-30
HRP20240670T1 (hr) 2024-09-27
AU2017272608A1 (en) 2018-12-06
HUE067450T2 (hu) 2024-10-28
AU2017272608B2 (en) 2023-08-10
MD3916392T2 (ro) 2024-10-31
NZ748468A (en) 2025-05-30
PL3465214T3 (pl) 2021-12-20
JP7511806B2 (ja) 2024-07-08
SMT202100291T1 (it) 2021-07-12
EA201892542A1 (ru) 2019-06-28
FI3916392T3 (fi) 2024-06-03
JP2019519770A (ja) 2019-07-11
ZA201808647B (en) 2021-05-26
JP7066639B2 (ja) 2022-05-13
MX388502B (es) 2025-03-20
ZA202100296B (en) 2025-05-28
CN109313194A (zh) 2019-02-05
EP3916392A1 (en) 2021-12-01
PL3916392T3 (pl) 2024-09-23
US20220283166A1 (en) 2022-09-08
SG10201911958SA (en) 2020-02-27
DK3916392T3 (da) 2024-05-21
MX2021014963A (es) 2022-02-24
CN115932265A (zh) 2023-04-07
EP3465214A1 (en) 2019-04-10
MA45124B1 (fr) 2021-05-31
WO2017207574A1 (en) 2017-12-07
PT3465214T (pt) 2021-06-30
CA3025823A1 (en) 2017-12-07
KR20190013980A (ko) 2019-02-11
PT3916392T (pt) 2024-06-04
DK3465214T3 (da) 2021-05-31
CY1124768T1 (el) 2022-11-25
BR112018074603A2 (pt) 2019-03-19
IL263103B2 (en) 2023-10-01
LT3465214T (lt) 2021-10-11
ES2878156T3 (es) 2021-11-18
IL263103B1 (en) 2023-06-01
MA45124A (fr) 2017-12-07
SMT202400204T1 (it) 2024-09-16
HUE054860T2 (hu) 2021-10-28
JP2022119764A (ja) 2022-08-17
MA57021B1 (fr) 2024-05-31
MX2018014702A (es) 2019-10-02
US20190195879A1 (en) 2019-06-27
MD3465214T2 (ro) 2021-09-30
EP3916392B1 (en) 2024-05-01
LT3916392T (lt) 2024-08-26
CN109313194B (zh) 2022-11-04
RS65540B1 (sr) 2024-06-28
SG11201810159TA (en) 2018-12-28
ES2981046T3 (es) 2024-10-07
HRP20210938T1 (hr) 2021-09-03
EP3465214B1 (en) 2021-04-28
RS62155B1 (sr) 2021-08-31
SI3465214T1 (sl) 2021-12-31
IL263103A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
KR102416144B1 (ko) 환자에서 항-cd19 치료법의 치료 이익의 예측 방법
EP4385569A2 (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
KR20220091576A (ko) 혈액암의 항-cd47 및 항-cd20 기반 치료
CN117065013A (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
US20220242952A1 (en) Anti-cd19 therapy in patients having a limited number of nk cells
HK40065007A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
TW201729832A (zh) 使用特異性結合ｃｄ３８之抗體免疫調節及治療固態腫瘤
HK40065007B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
HK40002753B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
EA040320B1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
NZ788788A (en) Methods for predicting therapeutic benefit of anti-CD19 therapy in patients
KR20220085796A (ko) 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
HK1254148A1 (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
OA16773A (en) BCMA-based stratification and therapy for multiple myeloma patients.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200529

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210810

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220411

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220629

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220630

End annual number: 3

Start annual number: 1

PG1601 Publication of registration